Critical Limb Ischemia (CLI)NCT03886506
Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
A study testing PLX-PAD in people with Critical Limb Ischemia (CLI), run by Pluristem Ltd. at 2 sites in United States.
Trial summary
A Phase III study of PLX-PAD for CLI patients with minor tissue loss who are unsuitable for revascularization has been initiated (PLX-CLI-03, PACE study). In parallel, this expanded access program (EAP) will be conducted to allow the treatment of patients who are ineligible to be enrolled in the PACE study. Read more about this study
- Who is it for?
- Ages 45 to 99 years
- Conditions the study is for
- Critical Limb Ischemia (CLI)
- What is being tested?
- PLX-PAD
- Type of treatment
- Injection or infusion
- How many people
- Not given
- Where
- 2 sitesUnited States
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 99 years
- All sexes
- Adult, Older adult
Who may be able to join
- Adult male or female subjects between ages 45 to 99 years of age at the time of screening.
- Subjects with a diagnosis of PAD due to atherosclerosis at the stage of CLI, with minor tissue loss up to the ankle level (ulcer/s and/or necrosis).
- Ankle pressure (AP)≤70 mmHg or toe pressure (TP)≤ 50 mmHg in the index leg or transcutaneous oxygen pressure (TcPO2)≤ 30 mmHg.
- Subject unsuitable for revascularization (by any method) in the index leg based on unfavorable risk-benefit assessment of the physician investigator. Unsuitability to revascularization should be based on any of the following:
- Anatomic considerations as: inappropriate target artery, diffuse/extensive tibial and/or peroneal artery lesions, inadequate distal run-off.
- Technical considerations as: inappropriate bypass conduit, failed recent revascularization.
Show all 19Show fewer
- Medical considerations: subject's comorbidities.
- Signed informed consent form.
- Additionally, this protocol includes subjects who are not eligible for the ongoing phase III study with PLX-PAD in CLI (PLX-CLI-03) due to at least one of the following criteria:
- Evidence of active localized osteomyelitis secondary to contiguous focus of infection, unless amputation is expected within 1 months post PLX-PAD administration. In case of osteomyelitis, patients must be treated with antibiotics during screening and PLX-PAD administration or as long as there is evidence of active infection.
- Subject on renal replacement therapy or with eGFR <15 mL/min.
- Current treatment with high dose systemic steroids (prednisone equivalent >7.5 mg/day) or topical steroids on the index leg.
- History of autologous bone marrow transplantation (if not due to hematologic malignancy) or solid organ transplantation, clinically stable.
- Immunocompromised subjects due to disease for any reason, including immunosuppressive therapy, at screening (for steroid therapy, refer to the criterion c)
- CLI with major tissue loss (Rutherford Category 6) in the contralateral leg.
- Diabetes mellitus with glycosylated hemoglobin (HbA1c) >10% at Screening.
- HIV controlled by antiretroviral therapy
- Past drug or alcohol abuse.
- Known history of cancer is eligible if occurred beyond 2 years before screening.
Who cannot join
- Non-atherosclerotic PAD and vasculitis (e.g., Buerger's disease [thromboangiitis obliterans], Takayasu's arteritis, etc.).
- CLI with major tissue loss (Rutherford Category 6) in the index leg. Ulcers from venous or neuropathic origin if not associated with at least one ulcer from arterial origin.
- Evidence of active infection in either leg (e.g., cellulitis, myositis) except localized osteomyelitis secondary to contiguous focus of infection, under antibiotic treatment.
- Subject having undergone surgical/endovascular revascularization or major/minor amputation, in either leg, less than 1 month prior to Screening.
- Planned or potential need for major/minor amputation or any revascularization of either leg within 1 month of EAP entry upon physician's judgment.
- Aortoiliac stenosis or common femoral artery stenosis or otherwise suspicion of inadequate inflow to the index leg at the time of Screening.
Show all 30Show fewer
- Current evidence or sign supporting an assessment of life expectancy of less than 6 months.
- Stroke or acute myocardial infarction within 3 months prior to Screening.
- Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV) at screening.
- Life-threatening ventricular arrhythmia - except in subjects with an implantable cardiac defibrillator at screening.
- Uncontrolled severe hypertension during Screening.
- Current or history of proliferative retinopathy.
- Known active Hepatitis B virus or Hepatitis C virus infections at Screening. Pluristem, Ltd Expanded Access Protocol
- Acquired immunodeficiency syndrome (AIDS), severe uncontrolled inflammatory disease,or severe uncontrolled autoimmune disease (e.g., ulcerative colitis, Crohn's disease, etc.).
- Subjects at an increased risk of blood clotting or bleeding according to the Physician's judgment.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×ULN. Subjects with higher levels may be included if the condition associated with the increase in those liver enzymes is known and is considered clinically stable.
- Current drug or alcohol abuse.
- Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending another investigational device or drug trial(s) unless in long-term follow-up phase (in which there is no IP administration).
- Current use or use within 30 days prior to screening of wound dressing containing cells or growth factors like Apligraf®, or topical platelet derived growth factor.
- Current use, planned use, or use within 15 days prior to treatment of hyperbaric oxygen therapy, spinal cord stimulation, or lumbar sympathectomy.
- Exposure to allogeneic cell based therapy in the past or exposure to autologous cell therapy in the last 12 months before screening.
- Known allergies to any of the following: dimethyl sulfoxide (DMSO), human serum albumin, bovine serum albumin.
- History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intravenous steroids/epinephrine, known allergy to more than 3 allergens, or in the opinion of the Physician the subject is at high risk of developing severe allergic/hypersensitivity reactions.
- History of severe atopic disease (including but not limited to chronic urticaria, respiratory allergy requiring oral steroids), or history of uncontrolled Asthma (Global Initiative for Asthma [GINA] III-IV).
- Pulmonary disease requiring supplemental oxygen treatment on a daily basis.
- History of acute transfusion reaction.
- History of allogeneic bone marrow transplantation.
- Active malignancy except for successfully resected skin basal cell carcinoma or not located on the index leg.
- Pregnant or lactation women
- Inability to understand and provide an informed consent.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
OBL-NJ Endovascular & Amputation Prevention, LLC,1429 Broad St., Clifton, NJ
Clifton, New Jersey, 07013
Holy Name Medical Center,718 Teaneck Road
Teaneck, New Jersey, 07666
About this study
Official title: Expanded Access to Provide Intramuscular Injections of PLX-PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
A Phase III study of PLX-PAD for CLI patients with minor tissue loss who are unsuitable for revascularization has been initiated (PLX-CLI-03, PACE study). In parallel, this expanded access program (EAP) will be conducted to allow the treatment of patients who are ineligible to be enrolled in the PACE study.
The EAP treatment is administered in addition to standard of care of the subjects.PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval. The locations of injections of the PLX-PAD are detailed in Appendix 1.
Antihistamine treatment should be given at least 1 hour and no more than 1.5 hours prior to PLXPAD administration to ensure coverage for 24 hours, and as long as necessary post PLX-PAD treatment. Consider treatment with second generation H1 inhibitors such as Cetirizine 10 mg once per day.Subjects will be followed-up until 12 months after the 2nd treatment according to the schedule of routine medical visits at the medical institutions. In addition to this routine follow-up, a phone call will be made 12 months after 2nd treatment to inquire on the occurrence of subsequent intervention, amputation, or death.
- Conditions
- Critical Limb Ischemia (CLI)
- Being tested
- PLX-PAD
- Medical subject headings
- Chronic Limb-Threatening Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PLX-PADBiological
PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical Limb Ischemia (CLI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Pluristem Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03886506
- Sponsor's protocol ID
- PLX-CLI-05
- Status last verified
- Sep 2024
- First submitted
- 19 Mar 2019
- Last updated
- 19 Sep 2024
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access to Provide Intramuscular Injections of PLX-PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
- ClinicalTrials.gov ID
- NCT03886506
- Acronym / sponsor ID
- PLX-CLI-05
- Conditions
- Critical Limb Ischemia (CLI)
- Study type
- Expanded access
- Recruitment status
- No Longer Available
- Lead sponsor
- Pluristem Ltd.Industry (pharma, biotech, devices)
- First posted
- 22 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase III study of PLX-PAD for CLI patients with minor tissue loss who are unsuitable for revascularization has been initiated (PLX-CLI-03, PACE study). In parallel, this expanded access program (EAP) will be conducted to allow the treatment of patients who are ineligible to be enrolled in the PACE study.
The EAP treatment is administered in addition to standard of care of the subjects.PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval. The locations of injections of the PLX-PAD are detailed in Appendix 1.
Antihistamine treatment should be given at least 1 hour and no more than 1.5 hours prior to PLXPAD administration to ensure coverage for 24 hours, and as long as necessary post PLX-PAD treatment. Consider treatment with second generation H1 inhibitors such as Cetirizine 10 mg once per day.Subjects will be followed-up until 12 months after the 2nd treatment according to the schedule of routine medical visits at the medical institutions. In addition to this routine follow-up, a phone call will be made 12 months after 2nd treatment to inquire on the occurrence of subsequent intervention, amputation, or death.
Study design
Who may qualify
- Ages
- 45 to 99 years
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Adult male or female subjects between ages 45 to 99 years of age at the time of screening.
- Subjects with a diagnosis of PAD due to atherosclerosis at the stage of CLI, with minor tissue loss up to the ankle level (ulcer/s and/or necrosis).
- Ankle pressure (AP)≤70 mmHg or toe pressure (TP)≤ 50 mmHg in the index leg or transcutaneous oxygen pressure (TcPO2)≤ 30 mmHg.
- Subject unsuitable for revascularization (by any method) in the index leg based on unfavorable risk-benefit assessment of the physician investigator. Unsuitability to revascularization should be based on any of the following:
- Signed informed consent form.
Key exclusion criteria (30 listed)
- Non-atherosclerotic PAD and vasculitis (e.g., Buerger's disease [thromboangiitis obliterans], Takayasu's arteritis, etc.).
- CLI with major tissue loss (Rutherford Category 6) in the index leg. Ulcers from venous or neuropathic origin if not associated with at least one ulcer from arterial origin.
- Evidence of active infection in either leg (e.g., cellulitis, myositis) except localized osteomyelitis secondary to contiguous focus of infection, under antibiotic treatment.
- Subject having undergone surgical/endovascular revascularization or major/minor amputation, in either leg, less than 1 month prior to Screening.
- Planned or potential need for major/minor amputation or any revascularization of either leg within 1 month of EAP entry upon physician's judgment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PLX-PADPLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval. | Biological | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2024.
Related trials for Critical Limb Ischemia (CLI)
Recruiting
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
Chronic Total Occlusion of Artery of the Extremities
Active, not recruitingObservational study
An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Peripheral Arterial Disease, Critical Lower Limb Ischemia
Recruiting
FAZA PET/MRI in CLI Patients Pre and Post Revascularization
Critical Limb Ischemia
Recruiting
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia
Active, not recruiting
LIFE-BTK PK Sub-study
Critical Limb Ischemia (CLI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PLX-PAD in people with Critical Limb Ischemia (CLI), run by Pluristem Ltd. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.